Vanderbilt investigators have demonstrated in two studies that metformin-based treatments delay the onset and progression of chronic kidney disease (CKD) compared with other treatments for diabetes.

Kidney disease is the eighth most common cause of death in the United States and affects more than 20 million people, yet many people don’t know they have kidney disease because it often develops very slowly and with minimal symptoms. For this reason, kidney disease is often referred to as a silent killer.

Vanderbilt University Medical Center, committed to providing multiple options to patients who have kidney disease, recently began offering nocturnal in-center hemodialysis, which allows patients to receive treatment at night while they sleep.

Targeting the production of molecules that promote tumor blood vessel development offers a new path for treating lung cancer.

Vanderbilt nephrologist, Thomas Golper, M.D., professor of Medicine in Nephrology and Hypertension, is leading an effort to form a research consortium with a goal of improving care for kidney failure patients who receive a form of home dialysis.

Seven Vanderbilt University faculty members named to endowed chairs were honored for outstanding academic achievements March 19 during a celebration at the Student Life Center.

The HIF oxygen-sensing pathway and its responses to low oxygen may be targeted for treatments of anemia and disorders of iron balance.